Format

Send to

Choose Destination
Pharmacol Res. 2014 Oct;88:84-98. doi: 10.1016/j.phrs.2014.06.013. Epub 2014 Jul 5.

Novel prospects of statins as therapeutic agents in cancer.

Author information

1
Department of Medicine and Surgery, University of Salerno, Italy; Department of Pharmacy, University of Salerno, Italy. Electronic address: spisanti@unisa.it.
2
Department of Medicine and Surgery, University of Salerno, Italy; Department of Pharmacy, University of Salerno, Italy.
3
Department of Medicine and Surgery, University of Salerno, Italy; Department of Pharmacy, University of Salerno, Italy. Electronic address: maubiful@unisa.it.

Abstract

Statins are well known competitive inhibitors of hydroxymethylglutaryl-CoA reductase enzyme (HMG-CoA reductase), thus traditionally used as cholesterol-lowering agents. In recent years, more and more effects of statins have been revealed. Nowadays alterations of lipid metabolism have been increasingly recognized as a hallmark of cancer cells. Consequently, much attention has been directed toward the potential of statins as therapeutic agents in the oncological field. Accumulated in vitro and in vivo clinical evidence point out the role of statins in a variety of human malignancies, in regulating tumor cell growth and anti-tumor immune response. Herein, we summarize and discuss, in light of the most recent observations, the anti-tumor effects of statins, underpinning the detailed mode of action and looking for their true significance in cancer prevention and treatment, to determine if and in which case statin repositioning could be really justified for neoplastic diseases.

KEYWORDS:

Adjuvant therapy; Anti-tumor immunity; Cancer; Mevalonate pathway; Statins

PMID:
25009097
DOI:
10.1016/j.phrs.2014.06.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center